Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户：bjiyguang

【摘要】

：

【作者】

：

Yongqing Zhang

【机构】

：

Department of Hematology,the 309th Hospital of PLA

【出处】

：

The 35th World Congress of the International Society of Hema

【发表日期】

：

2014年5期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

The PAD regime,composed of bortezomib,adriamycin and dexamethasone,improves the outcomes of patients with advanced multiple myeloma (MM),but at the same time produces high frequency of serious toxic side effects.For the first time,we evaluated the efficacy and safety of a bortezomib-dose-reduced PAD regime in the treatment of relapsed/refractory MM in this clinical study.

其他文献

Report of Series Data Set for 40 samples from HAPC groups-using inflammation array

Aim To analysis the diversity of inflammation agents expression in the patients of high altitude polycythemia(HAPC).Methods the serum specimen of 20 cases and 20 controls were collected.The serum spec

会议

Administration of novel agents in the frontline therapy improved overall survival of patients with m

Background Treatments for multiple myeloma (MM) have dramatically improved now.The immunomodulatory drug (IMiDs) thalidomide and proteasome inhibitor (PI) bortezomib are administrated to patients with

会议

The applicability of the International Staging System in Chinese patients with multiple myeloma rece

Objective The International Staging System (ISS) is an important prognostic indicator for outcome of patients with multiple myeloma (MM).ISS was proposed in 2005 using data from 10,750 MM patients who

会议

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as indu

Objective Novel agents-based anti-myeloma regimens including thalidomide and bortezomib have significantly improved myeloma treatment.However,it remains unclear whether patients will benefit more from

会议

Differential gene expression profile and biological features of bone marrow mesenchymal stem cells i

Objective High altitude polycythemia (HAPC) is characterized by excessive erythrocytes and enhanced angiogenesis,which is caused by environmental factors such as hypoxia and cold at high altitude.Howe

会议

Molecular Cytogenetic Aberrations in Thai Patients with Multiple Myeloma Ramathibodi Experience

Introduction Cytogenetic abnormality plays an important role in prognosis of patients with multiple myeloma (MM).Conventional cytogenetic assay reveals limited results.In this study,we performed inter

会议

Fluorescence in situ hybridization detection of cytogenetic abnormalities and prognosis in multiple

Background Multiple myeloma (MM) is a plasma-cell malignancy manifested accumulation of abnormal plasma cells in the bone marrow.The purpose of this study is to evaluate the prognosis in patients with

会议

Protein Turnover Assay (ProTA) A Novel Tool For Profiling Human Protein Degradome to Elucidate Cellu

Purpose Global change in protein turnover (protein degradome) constitutes a central part of cellular responses to intrinsic or extrinsic stimuli.However,profiling protein degradome remains technically

会议

Fenretinide effects myeloma side population mediating tha reactive oxygen species-dependent mechanis

Tumor initiating cells play important roles in multiple myeloma (MM) progression,relapse,recurrence,and are critical target for therapy.However,quite few agents have been shown to target tumor initiat

会议

Bortezomib-Based Versus Nonbortezomib-Based Post-Transplantation Treatment in Multiple Myeloma Patie

Objective The aim of this meta-analysis of data from phase Ⅲ studies is to characterize efficacy and safety of bortezomib-based versus nonbortezomib-based post-transplantation therapy in patients with

会议

Modified Bortezomib, Adriamycin and Dexamethasone (PAD) Regimen in Advanced Multiple Myeloma

与本文相关的学术论文